Literature DB >> 35998976

Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD.

Craig Ostroff1, Ronald D Perrone2, Frank S Czerwiec3.   

Abstract

Entities:  

Keywords:  ADPKD; accelerated approval; biomarker; clinical trial; glomerular filtration rate; total kidney volume

Year:  2022        PMID： 35998976      PMCID： PMC9528266          DOI： 10.2215/CJN.05360522

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  7 in total

1.  The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Annick Rousseau; Maryvonne Hourmant; Eric Renaudineau; Christophe Charasse; Marie-Pascale Morin; Marie-Christine Moal; Jacques Dantal; Bassem Wehbe; Régine Perrichot; Thierry Frouget; Cécile Vigneau; Jérôme Potier; Philippe Jousset; Marie-Paule Guillodo; Pascale Siohan; Nazim Terki; Théophile Sawadogo; Didier Legrand; Victorio Menoyo-Calonge; Seddik Benarbia; Dominique Besnier; Hélène Longuet; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2015-07-06       Impact factor: 10.121

2.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Authors:  María V Irazabal; Laureano J Rangel; Eric J Bergstralh; Sara L Osborn; Amber J Harmon; Jamie L Sundsbak; Kyongtae T Bae; Arlene B Chapman; Jared J Grantham; Michal Mrug; Marie C Hogan; Ziad M El-Zoghby; Peter C Harris; Bradley J Erickson; Bernard F King; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

3.  Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).

Authors:  Kimberly A Smith; Aliza M Thompson; David A Baron; Steven T Broadbent; Gary H Lundstrom; Ronald D Perrone
Journal:  Am J Kidney Dis       Date:  2018-12-29       Impact factor: 8.860

4.  Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.

Authors:  Dorothee Oberdhan; Jason C Cole; Holly B Krasa; Rebecca Cheng; Frank S Czerwiec; Ron D Hays; Arlene B Chapman; Ronald D Perrone
Journal:  Am J Kidney Dis       Date:  2017-11-14       Impact factor: 8.860

5.  Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned.

Authors:  Haihao Sun; Jean W Temeck; Wiley Chambers; Ginger Perkins; Renan Bonnel; Dianne Murphy
Journal:  Ther Innov Regul Sci       Date:  2017-08-18       Impact factor: 1.778

6.  Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva
Journal:  N Engl J Med       Date:  2017-11-04       Impact factor: 91.245

Review 7.  Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease.

Authors:  Melissa A Cadnapaphornchai
Journal:  Front Pediatr       Date:  2017-03-23       Impact factor: 3.418
  7 in total
  1 in total

1.  Drug Development for Cystic Kidney Diseases.

Authors:  Sorin Fedeles; Ronald D Perrone
Journal:  Clin J Am Soc Nephrol       Date:  2022-08-23       Impact factor: 10.614
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.